2026 Hereditary Cancer Genetics: Incorporation into Clinical Care

2026 Hereditary Cancer Genetics: Incorporation into Clinical Care is organized by Memorial Sloan Kettering Cancer Center (MSKCC) and will be held from Sep 17 - 18, 2026 at Mortimer B. Zuckerman Research Center - Sloan Kettering Institute, New York City, New York, United States of America.

Description:
This two-day conference provides comprehensive professional training in clinical cancer genetics, hosted by Memorial Sloan Kettering Cancer Center (MSK) — one of the nation’s largest cancer genetics centers. The program features expert faculty with specialized expertise in disease-specific management and offers opportunities for participants to engage directly with speakers through panel discussions and case-based presentations. The course is designed to establish a strong foundation in cancer genetics, examine the clinical implications of genetic testing for patient care, and highlight emerging advances in cancer genomics.

Program Highlights:

• Current topics in hereditary breast, gynecologic, gastrointestinal, genitourinary, and pediatric cancers
• Hereditary hematologic malignancies and rare cancer syndromes
• Surveillance strategies and precision oncology
• Advances and research in diagnosis, early detection, and cancer prevention strategies
• Multidisciplinary panel discussions and case studies
• Networking opportunities, including a reception on Friday evening 

Objectives:

1. Identify clinical features of hereditary cancer predisposition syndromes and facilitate interpretation of genetic test results
2. Evaluate the recommended surveillance and risk reduction interventions for patients with hereditary cancer predisposition syndromes
3. Enhance awareness of implications of germline genetic testing on therapeutic management of patients with cancer, including oncological and surgical interventions
4. Apply concepts of germline variant analysis and tumor profiling to enhance clinical care of patients at risk for hereditary cancer syndromes
5. Discuss novel advances and technologies to help improve the early detection of hereditary cancers